2 results
Approved WMORecruiting
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
Approved WMOCompleted
Primary objective:To demonstrate the efficacy of Rifaximin -EIR 400 mg Tablet (800mg /BID, total daily dose 1600 mg) versus placebo in the prevention of endoscopic Crohn*s disease recurrence following ileocolonic resection